

**Alameda Alliance for Health**  
1240 South Loop Road  
Alameda, CA 94502

Location: Cisco Webex, 1-408-418-9388  
Meeting ID: 187 298 5906  
Password: fGpyi2Cam25

**IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS**

AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES.

YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO "ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE" 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT [mflorian@alamedaalliance.org](mailto:mflorian@alamedaalliance.org). YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK <https://alamedaalliance.webex.com/alamedaalliance> OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: 1-408-418-9388. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MUST SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE.

**PLEASE NOTE:** THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. IT WOULD BE APPRECIATED IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING. IF THAT IS NOT POSSIBLE, EVERY EFFORT WILL BE MADE TO ATTEMPT TO REVIEW E-COMMENTS DURING THE COURSE OF THE MEETING. TOWARDS THIS END, THE CHAIR OF THE COMMITTEE WILL ENDEAVOR TO TAKE A BRIEF PAUSE BEFORE ACTION IS TAKEN ON ANY AGENDA ITEM TO ALLOW THE COMMITTEE CLERK TO REVIEW E-COMMENTS, AND SHARE ANY E-COMMENTS RECEIVED DURING THE MEETING.

## AGENDA

ITEM	DESCRIPTION	TIME	VOTE
I)	<b>Call to order</b> <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i>		
	<ul style="list-style-type: none"> <li>Conflict of Interest Check/Disclosure</li> <li>Agenda Overview</li> </ul>	2 min	-
II)	<b>Informational Updates</b> <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>		
	<ul style="list-style-type: none"> <li>Welcome Dr. Dao</li> <li>Dr. Watts Departure</li> <li>Pharmacy Carve-out Postponed</li> <li>NCQA Audit</li> <li>DMHC/DHCS Regulatory Audits</li> <li>ECM &amp; ILOS</li> <li>COVID-19 Vaccine Outreach to Medi-Cal &amp; Group Care Members</li> </ul>	15 min	-
III)	<b>Pharmacy Utilization Reports (Quarter 4)</b> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>		
	<ul style="list-style-type: none"> <li>Top 50 Drugs by Cost</li> <li>Top 100 PA Reviewed Drugs</li> </ul>	2 min	-

**IV) E-Voting Material/Consent Agenda**

**The following items have been sent to the voting committee for review via E-voting**

*Rahel Negash, PharmD, Pharmacist, Alameda Alliance*

*(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)*

Monographs/Class Reviews	Changes
Parkinson's Disease	<ul style="list-style-type: none"> <li>No change</li> </ul>
Antiplatelet Agents	<ul style="list-style-type: none"> <li>No change</li> </ul>
Low Molecular Weight Heparins	<ul style="list-style-type: none"> <li>No change</li> </ul>
PCSK9 inhibitors	<ul style="list-style-type: none"> <li>PA criteria: Update bulleting indentations, remove preferred NDCs</li> </ul>
Second Generation Antihistamines	<ul style="list-style-type: none"> <li>PA criteria: update OTC and brand name status of Pazeo/Pataday 0.7%</li> </ul>
Medication Request Guidelines	Changes
Estrogen Patches and Injectables	<ul style="list-style-type: none"> <li>Correct FRAX score as greater than or equal to (instead of greater than) 3 and greater than or equal to (instead of greater than) 20 percent.</li> </ul>
Cystic Fibrosis Agents	<ul style="list-style-type: none"> <li>Add generic Bethkis under inhaled tobramycin products</li> </ul>
Antibiotic Eye Medications	<ul style="list-style-type: none"> <li>Change brand generic status of Moxeza</li> </ul>
Drugs for Gender Dysphoria For Less Than 21 Years Old	<ul style="list-style-type: none"> <li>Add dosage forms to non-formulary section: Androgel 1.62% packets, Fensolvi (leuprolide acetate) syringe kit</li> <li>Remove Striant: off market</li> </ul>
Drugs for Gender Dysphoria For At Least 21 Years Old	<ul style="list-style-type: none"> <li>Add dosage forms to non-formulary section: Androgel 1.62% packets, Fensolvi (leuprolide acetate) syringe kit</li> <li>Remove Striant: off market</li> </ul>
Testosterone Agents	<ul style="list-style-type: none"> <li>Add dosage form to non-formulary section: Androgel 1.62% packets</li> <li>Remove Striant: off market</li> </ul>
Synagis	<ul style="list-style-type: none"> <li>Correction of 50mg strength in medications section</li> </ul>
Injectable/Specialty Medications	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Atovaquone (Mepron)	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Tadalafil (Cialis) for BPH	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Elmiron (pentosane polysulfate)	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Ezetimibe (Zetia)	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Altoprev (lovastatin ER) and	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Symlin (pramlintide)	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Histamine H2 Receptor Antagonists	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Topical Acne Agents	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Tranexamic acid (Lysteda)	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Linezolid	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Criteria for short acting opioid	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Pyridostigmine (Mestinon)	<ul style="list-style-type: none"> <li>No changes</li> </ul>

10  
min

**EV**

Corticosteroid Preparations to Treat	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Diuretics	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Antihypertensives	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Savella (milnacipran) tablet	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Travoprost (Travatan Z) ophthalmic	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Arikayce (amikacin)	<ul style="list-style-type: none"> <li>No changes</li> </ul>
Oxbryta (voxelotor)	<ul style="list-style-type: none"> <li>No changes</li> </ul>
<b>Interim Formulary changes</b>	
<ul style="list-style-type: none"> <li>See p. 210 in packet</li> </ul>	
<b>Pharmacy Policy &amp; Procedure Updates</b>	
RX-001-Pharmaceutical Operating Processes Summary	<ul style="list-style-type: none"> <li>Remove MCAL LOB &amp; DHCS directive language for Operating Processes</li> </ul>
RX-002 -PA Review Process	<ul style="list-style-type: none"> <li>Remove MCAL LOB &amp; DHCS directive language for PA Review Process</li> <li>Remove deferral and gender language</li> </ul>
RX-003 Exception Review Process	<ul style="list-style-type: none"> <li>Remove MCAL LOB &amp; DHCS directive language for Exception Review Process</li> <li>Remove gender limit override</li> <li>Clarify Continuation of therapy override (include OTC products)</li> </ul>
RX-004-Formulary Management	<ul style="list-style-type: none"> <li>Remove MCAL LOB &amp; DHCS directive language for Formulary Management</li> <li>Remove Carve Out to Medi Cal FFS reference</li> </ul>
RX-005 P&T Committee Roles and Scope	<ul style="list-style-type: none"> <li>Remove MCAL LOB &amp; DHCS directive language for P&amp;T Committee Roles and Scope</li> <li>Include fax for formulary change requests</li> </ul>
RX-006-Pharmacy Services Staff Description	<ul style="list-style-type: none"> <li>Remove MCAL LOB &amp; DHCS directive language for Pharmacy Services Staff Description</li> <li>Update PBM Pharmacy job titles</li> </ul>
RX-007-Pharmaceutical Patient Safety	<ul style="list-style-type: none"> <li>Remove MCAL LOB &amp; DHCS directive language for Pharmaceutical Patient Safety</li> <li>Add QI to Alliance internal staff list</li> </ul>
RX-008-PBM Delegated Audit Oversight	<ul style="list-style-type: none"> <li>Remove MCAL LOB &amp; DHCS directive language for PBM Delegated Audit Oversight</li> <li>Add Compliance Committee as another recipient of audit findings</li> <li>Present quarterly performance measures summary report findings to P&amp;T Committee, not P&amp;T Sub Committee</li> </ul>
RX-009-Emergency Supply Provision	<ul style="list-style-type: none"> <li>Remove MCAL LOB &amp; DHCS directive language for Pharmaceutical Emergency Supply Provision</li> </ul>

RX-010 Drug Utilization Management	<ul style="list-style-type: none"> <li>Will utilize Magellan data (for MCAL) to assist with coordination of care in collaboration with case management</li> <li>Will report annual Magellan data (for MCAL) DUR to DHCS &amp; attend global DUR meeting</li> </ul>
Rx-011 Decision and Notification Requirements	<ul style="list-style-type: none"> <li>Remove MCAL LOB &amp; DHCS directive language for Decision and Notification Requirements</li> <li>Update TAT to only reflect GC 24hr urgent or 72hr non-urgent requests</li> </ul>
RX-012-Designated Users (DU) to the Medi-Cal Rx secure MCP Pharmacy Portal and DU Access Request utilization of Medi-Cal RX	<ul style="list-style-type: none"> <li>Identification of Designated Users (DU) to the Medi-Cal Rx secure MCP Pharmacy Portal</li> <li>Submission, maintenance and tracking of Designated User lists</li> <li>How to respond if the MCP Pharmacy Portal system is down</li> </ul>
<b>P&amp;T Charter Update</b>	
<ul style="list-style-type: none"> <li>Remove section (h) from voting member category</li> </ul>	
<b>P&amp;T Meeting Minutes</b>	
<ul style="list-style-type: none"> <li>P&amp;T Meeting Minutes Q4 December 15, 2020</li> </ul>	

**ADJOURN TO CLOSED SESSION** (Pursuant to California Government Code Title 5, §54954.5(h))

*Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes  
Estimated Date of Public Disclosure: 3/16/2021 (formulary changes only; no trade secrets will be disclosed).*

**V) New Business**

*Natalee Felten, PharmD, Pharmacist, PerformRx*

- New MRG:** Biologic Agents for Nasal Polyposis
- Physician Administered Drug (PAD) Medication Request Guideline Document

**New:**

- Oxlumo

**Revise:**

- Anti-CD20 Monoclonal Antibodies (mAb)
- Ophthalmic indications for bevacizumab
- Immunoglobulin Therapy (IVIG)
- Specialty Biological Agents for Systemic Juvenile Idiopathic Arthritis
- Specialty Biological Agents for Uveitis
- Specialty Biological Agents for Hidradenitis Suppurativa
- Specialty Biological Agents for Giant Cell Arteritis
- Injectable/Specialty Medications
- Oral and Injectable Oncology Medications

45  
min

V

**VI) Class Reviews, Monographs, and Recommendations**

*Rahel Negash, PharmD, Pharmacist, Alameda Alliance*

- Renin Angiotensin Aldosterone System (RAAS) Agents
- Pulmonary Arterial Hypertension

**VII) Medication Request Guidelines**

*Rahel Negash, PharmD, Pharmacist, Alameda Alliance*

1. Xolair (omalizumab)
2. Eosinophilic Asthma Agents
3. Thrombocytopenia Agents
4. Idiopathic Pulmonary Fibrosis
5. Trelegy Ellipta
6. Aptiom (eslicarbazepine)

**VIII) Summary of Closed Session**

*Helen Lee, PharmD, MBA, Senior Pharmacy Director – Alameda Alliance*

**RECONVENE IN OPEN SESSION**

ITEM	DESCRIPTION	TIME	VOTE
IX)	<b>Informational Updates on New Developments in Pharmacy</b> <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i>	2 min	-
	• New Product Review		
X)	<b>Old Business</b>	0 min	
	• None		
XI)	<b>Public Comment</b>	0 min	-
XII)	<b>Adjournment</b>		
	• P&T Committee Member Forms		

**ACTION / FOLLOW-UP ITEMS**

ITEM	DUE DATE	RESPONSIBLE

**FUTURE P&T MEETINGS**

NEXT MEETING	2021 P&T MEETINGS
June 15th, 2021	September 21st, 2021
	December 21st, 2021

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

**Note:** Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or [hlee@alamedaalliance.org](mailto:hlee@alamedaalliance.org) at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.